Extended Data Fig. 3: Validation of cancer drug addiction variant phenotypes.
From: Base editing screens define the genetic landscape of cancer drug resistance mechanisms
a) Western blotting of drug resistance variants from base editing screens in HT-29 cells conferring resistance to dabrafenib and cetuximab combination therapy. HT-29 cells harbouring the indicated variants were treated with dabrafenib (80 nM) and cetuximab (1 µg/ml) or DMSO (control) for 24 h before analysis. Data are representative of two independent experiments (see also Fig. 2). b) Microscopy images of ß-galactosidase assays performed to measure the induction of senescence. HT-29 cells harbouring the indicated variants were treated with dabrafenib (80 nM) and cetuximab (1 µg/ml) or DMSO (control) for 48 h before analysis. Representative images from two independent experiments. Scale bar indicates 500 µm. Genotyped variants are shown.
